The GRU Cancer Center has been awarded a five-year grant from the National Cancer Institute (NCI) to lead an NCI Community Oncology Research Program (NCORP) Minority/Underserved Community Site. Working in partnership with the Morehouse School of Medicine (Atlanta), University Cancer and Blood Center (Athens) and the Jiann-Ping Hsu College of Public Health at Georgia Southern University (Statesboro), GRU Cancer Center will use the grant to increase awareness of and participation in NCI-sponsored clinical trials and cancer care delivery research throughout Georgia, particularly among minority and underserved populations.
The NCORP replaces both the NCI Community Clinical Oncology Program (CCOP) and the NCI Community Cancer Centers Program (NCCP) and is an essential component of the national cancer clinical trials enterprise.
As the only NCORP Minority/Underserved Community Site for Georgia, and one of just 12 selected nationally, the GRU Cancer Center–led consortium will contribute to the design, conduct and translation of the national NCORP research agenda, particularly studies pertaining to minority and underserved populations. Key stakeholders and community partners will be engaged to learn their priorities for community-based cancer research and to work collectively to address the historic barriers that have stood in the way of minority and underserved patients participating in clinical trials and other important cancer research.
“We are thrilled with this award which will enable us to build upon more than a decade of experience serving as a Minority-Based CCOP,” said Dr. Samir N. Khleif, director of the GRU Cancer Center. “And, we appreciate NCI’s confidence in the ability of the GRU Cancer Center and our outstanding NCORP partners to positively impact the tremendous cancer health disparities that exist in Georgia among minorities and medically underserved populations. This grant is in perfect alignment with our shared commitment to serve all Georgians with the best possible cancer care.”
The GRU Cancer Center is a multi-disciplinary academic cancer center focused on both research and clinical treatment. Its patient-centered approach to treatment includes first-in-the-nation treatment protocols, an experimental therapeutics program that includes specialized clinics for Phase I trials and immunotherapy and a variety of ancillary programs – including music therapy and genetic counseling – designed with holistic healing in mind.